A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0268-0965 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Insulin (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 20 Dec 2019 Status changed from active, no longer recruiting to completed.
- 02 Dec 2019 Planned End Date changed from 19 Oct 2019 to 18 Dec 2019.
- 02 Dec 2019 Planned primary completion date changed from 28 Sep 2019 to 18 Dec 2019.